ProCE Banner Series

Integrating BCMA-Targeted Therapies Into R/R Multiple Myeloma Care: Opportunities for Pharmacists

Join us for this 1-hour webinar with a live Q&A session where experts discuss the latest data on their approaches for incorporating BCMA-targeted therapies into care plans for patients with R/R multiple myeloma, including guidance on monitoring and mitigating potential adverse events.

In coordination with HOPA's Annual Conference

  ACPE-P
Credits Available

1.0

Who Should Attend

The target audience is pharmacists who care for patients with R/R MM as well as other stakeholders in hematology/oncology practice.

All Events

Integrating BCMA-Targeted Therapies Into R/R Multiple Myeloma Care: Opportunities for Pharmacists

Past Events

May

04

2023

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Topics

HOPA 2023: Integrating BCMA-Targeted Therapies Into R/R Multiple Myeloma Care: Opportunities for Pharmacists

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge, confidence, and competence of learners in applying practice-changing clinical data and expert recommendations to integrate the use of BCMA-targeted agents for their patients with R/R MM.

Target Audience
The target audience is pharmacists who care for patients with R/R MM as well as other stakeholders in hematology/oncology practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Explain the treatment role of novel BCMA-targeted therapies, including antibody–drug conjugates, bispecifics, and CAR T-cell therapy in R/R MM
  • Select personalized, evidence-based treatment regimens with BCMA-targeted therapies considering available efficacy, safety, tolerability data along with guideline and expert recommendations, patient preference, disease prognosis, and functional status
  • Monitor and mitigate potential adverse events from anti-BCMA therapy, including but not limited to ocular toxicity, cytokine-release syndrome, and neurotoxicity

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-010-L01-P has been assigned to this live application-based activity (initial release date 5/4/2023). This activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by ProCE, LLC.

In partnership with Clinical Care Options, LLC and the Hematology/Oncology Pharmacy Association (HOPA).

Supported by an educational grant from Bristol-Myers Squibb.

Add From Media LibraryContact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191